Bioxcel therapeutics submits pre-supplemental new drug application meeting package in support of potential label expansion for igalmi®

Company focused on obtaining approval for outpatient (at-home) use of igalmi® for the acute treatment of agitation associated with bipolar disorders or schizophrenia

BTAI Ratings Summary

BTAI Quant Ranking